Eli Lilly & Company
Exenatide dose reduced postprandial plasma glucose excursions in type 2 diabetes
Published in Law and Health Weekly, April 15th, 2006
"Exenatide is an incretin mimetic whose effect on glycemic control in patients with type 2 diabetes is currently under investigation. This study assessed the effect of injection time relative to a standardized meal on postprandial pharmacodynamics of exenatide in patients with type 2 diabetes," researchers in England report.
H. Linnebjerg and colleagues at Eli Lilly explained, "Eighteen patients participated in this single-center, open-label, placebo-controlled, randomized, six-way crossover study. Patients received subcutaneous injections of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- American College of Cardiology
Researchers find viable new sources for stem cell transplants to the heart - Colon Cancer
Physicians warn too few Americans getting screened for colon cancer - End-of-Life Issues
Advance planning can help family members make decisions at end of life - Evercare
Evercare launches educational outreach program to answer Medicare Part D questions - Inex Pharmaceuticals Corp.
Inex licenses three targeted chemotherapy products to Hana Biosciences - Information Technology
Verispan's informatics software identifies top 10 drug classes affected by Medicare Part D - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
